Skip to Main Content

Paper Details

Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors.
Am J Hematol
22
2022
Author NameAffiliation
Borko JovanovicNorthwestern University Feinberg School of Medicine
  • 1 - 1

Datasets

Release 1.2